With a long history of conducting comprehensive research and working towards commercialisation of the regenerative medicine for hair, (Shiseido NZ) has announced plans to open a new research facility dedicated to hair regeneration.
The Shiseido Cell-Procession and Expansion Center will open on May 1 and will focus on the research and development of hair regenerative medicine with an aim towards commercialisation. This area has huge earning potential for Shiseido, estimated to be around 200 billion yen in Japan alone.
The Japanese Government is approving new legislation and revisions to existing laws in order to advance regenerative medicine in Japan. The centre will be located in the Kobe Biomedical Innovation Cluster, a special zone designated by the Japanese Government to promote industrial development in advanced medicine and to provide a competitive advantage in the international market.
The centre follows Shiseido’s acquisition of the exclusive geographic licence to use RepliCel’s RCH-01 regeneration technology across Asia last year. RCH-01 is an autologous cell transplantation technology” in which cells from hair follicles are taken from a patient and cultured before being injected into the balding scalp area. This process aims to stimulate residing hair follicles and promote new growth in the balding scalp area.
